Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Cancelled Post Market

Current status date:

2022-10-01

Original market date: See footnote 1

2010-12-14

Lot number: See footnote 2

41174DK

Expiry date: See footnote 2

2024-05-01

Product name:

ROPIVACAINE HYDROCHLORIDE INJECTION USP

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02347822

Product Monograph/Veterinary Labelling:

Date: 2020-05-19 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

PFIZER CANADA ULC
17300 Trans-Canada Highway
Kirkland
Quebec
Canada H9J 2M5

Class:

Human

Dosage form(s):

Solution

Route(s) of administration:

Epidural ,  Block/Infiltration

Number of active ingredient(s):

1

Schedule(s):

Ethical

 

American Hospital Formulary Service (AHFS): See footnote 3

72:00.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

N01BB09 ROPIVACAINE

Active ingredient group (AIG) number:See footnote5

0133273003

List of active ingredient(s)
Active ingredient(s) Strength
ROPIVACAINE HYDROCHLORIDE 5 MG / ML
Version 4.0.2
Date modified: